Skip to main content
NCBI home page
Indian Journal of Psychiatry logoLink to Indian Journal of Psychiatry
. 2001 Jul-Sep;43(3):257–263.

OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA : AN OPEN LABEL COMPARATIVE CLINICAL TRIAL FROM NORTH INDIA

Ajit Avasthi *,*, Parmanand Kulhara †, Neeraj Kakkar ‡
PMCID: PMC2956152  PMID: 21407865

Abstract

The aim of the present study was to assess the efficacy and safety of olanzapine in the treatment of schizophrenic patients. 27 patients were randomly assigned to treatment with olanzapine or haloperidol over 12 weeks. The primary efficacy measure was the mean change from baseline to endpoint in total scores on the Brief Psychiatric Rating Scale (BPRS) and assessing treatment emergent adverse events. Secondary measures were positive symptoms, negative symptoms, general psychopathology depression, anxiety and quality of life. Compared to haloperidol, olanzapine had equal effect in improving overall psychopathology, positive symptoms, and severity of schizophrenic illness. Olanzapine showed supehor improvement on negative symptoms and secondary depressive features. Commonest side effects were weight gain, sleepiness and increased duration of sleep. Olanzapine is effective in improving overall psychopathology including positive symptoms, negative and secondary depressive features in Indian patients with schizophrenia and it is safe and well tolerated at dosage between 5 to 20 mg/day

Keywords: Olanzapine, schizophrenia, treatment

Full Text

The Full Text of this article is available as a PDF (304.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes T. R. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 May;154:672–676. doi: 10.1192/bjp.154.5.672. [DOI] [PubMed] [Google Scholar]
  2. Beasley C. M., Jr, Hamilton S. H., Crawford A. M., Dellva M. A., Tollefson G. D., Tran P. V., Blin O., Beuzen J. N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997 May;7(2):125–137. doi: 10.1016/s0924-977x(96)00392-6. [DOI] [PubMed] [Google Scholar]
  3. Beasley C. M., Jr, Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996 Mar;124(1-2):159–167. doi: 10.1007/BF02245617. [DOI] [PubMed] [Google Scholar]
  4. Beasley C. M., Jr, Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996 Feb;14(2):111–123. doi: 10.1016/0893-133X(95)00069-P. [DOI] [PubMed] [Google Scholar]
  5. Bymaster F. P., Calligaro D. O., Falcone J. F., Marsh R. D., Moore N. A., Tye N. C., Seeman P., Wong D. T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87–96. doi: 10.1016/0893-133X(94)00129-N. [DOI] [PubMed] [Google Scholar]
  6. Bymaster F., Perry K. W., Nelson D. L., Wong D. T., Rasmussen K., Moore N. A., Calligaro D. O. Olanzapine: a basic science update. Br J Psychiatry Suppl. 1999;(37):36–40. [PubMed] [Google Scholar]
  7. Carlsson A. Neurocircuitries and neurotransmitter interactions in schizophrenia. Int Clin Psychopharmacol. 1995 Sep;10 (Suppl 3):21–28. [PubMed] [Google Scholar]
  8. Casey D. E. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 1996;57 (Suppl 11):40–52. [PubMed] [Google Scholar]
  9. Harrow M., Yonan C. A., Sands J. R., Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull. 1994;20(2):327–338. doi: 10.1093/schbul/20.2.327. [DOI] [PubMed] [Google Scholar]
  10. Heinrichs D. W., Hanlon T. E., Carpenter W. T., Jr The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10(3):388–398. doi: 10.1093/schbul/10.3.388. [DOI] [PubMed] [Google Scholar]
  11. Hemrick-Luecke S. K., Snoddy H. D., Fuller R. W. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 1994;55(7):479–483. doi: 10.1016/0024-3205(94)00739-x. [DOI] [PubMed] [Google Scholar]
  12. Kane J. M., Mayerhoff D. Do negative symptoms respond to pharmacological treatment? Br J Psychiatry Suppl. 1989 Nov;(7):115–118. [PubMed] [Google Scholar]
  13. Kane J. M. Treatment of schizophrenia. Schizophr Bull. 1987;13(1):133–156. doi: 10.1093/schbul/13.1.133. [DOI] [PubMed] [Google Scholar]
  14. Kirkpatrick B., Carpenter W. T., Jr Drug development and the deficit syndrome of schizophrenia. Biol Psychiatry. 1995 Sep 1;38(5):277–278. doi: 10.1016/0006-3223(95)00350-P. [DOI] [PubMed] [Google Scholar]
  15. Meltzer H. Y. Clozapine: is another view valid? Am J Psychiatry. 1995 Jun;152(6):821–825. doi: 10.1176/ajp.152.6.821. [DOI] [PubMed] [Google Scholar]
  16. Meltzer H. Y. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 1991;17(2):263–287. doi: 10.1093/schbul/17.2.263. [DOI] [PubMed] [Google Scholar]
  17. Montgomery S. A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382–389. doi: 10.1192/bjp.134.4.382. [DOI] [PubMed] [Google Scholar]
  18. Simpson G. M., Angus J. W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19. doi: 10.1111/j.1600-0447.1970.tb02066.x. [DOI] [PubMed] [Google Scholar]
  19. Tollefson G. D., Beasley C. M., Jr, Tran P. V., Street J. S., Krueger J. A., Tamura R. N., Graffeo K. A., Thieme M. E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997 Apr;154(4):457–465. doi: 10.1176/ajp.154.4.457. [DOI] [PubMed] [Google Scholar]
  20. Tollefson G. D., Sanger T. M., Lu Y., Thieme M. E. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 1998 Mar;55(3):250–258. doi: 10.1001/archpsyc.55.3.250. [DOI] [PubMed] [Google Scholar]
  21. Tollefson G. D., Sanger T. M. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry. 1997 Apr;154(4):466–474. doi: 10.1176/ajp.154.4.466. [DOI] [PubMed] [Google Scholar]
  22. Tran P. V., Dellva M. A., Tollefson G. D., Beasley C. M., Jr, Potvin J. H., Kiesler G. M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 1997 May;58(5):205–211. doi: 10.4088/jcp.v58n0505. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES